Department of Medicine, University of California at San Francisco, San Francisco, CA 94121, USA.
Am J Respir Crit Care Med. 2013 Feb 15;187(4):417-23. doi: 10.1164/rccm.201206-1025OC. Epub 2012 Dec 13.
Lung transplantation offers great promise for otherwise terminal lung diseases, but the development of bronchiolitis obliterans syndrome (BOS) continues to limit survival. Although acute rejection and lymphocytic bronchiolitis have been identified as risk factors for the development of BOS, it is unclear whether large-airway lymphocytic inflammation conveys the same risk.
We evaluated lymphocytic bronchitis on endobronchial biopsies as a risk factor for BOS and mortality.
Endobronchial biopsies were collected and graded during surveillance after lung transplantation. We assessed samples with negative cultures collected in the first 90 days from 298 subjects and compared large-airway lymphocytic bronchitis assessed by a 0-2 "E-score" and with standard A and BR pathology scores for acute rejection and small-airway lymphocytic bronchiolitis, respectively.
We found surprisingly little association between large- and small-airway lymphocytic inflammation scores from a given bronchoscopy. Endobronchial lymphocytic bronchitis was more prevalent in subjects in BOS stage 0p and BOS stages 1-3 at the time of biopsy. Within 90 days after transplantation, increasing maximum E-score was associated with greater risk of BOS (adjusted hazard ratio, 1.76; 95% confidence interval, 1.11-2.78; P = 0.02) and in this analysis 90-day maximum E-scores were the only score type predictive of BOS (P < 0.01).
These results support a multicenter study to evaluate endoscopic biopsies for the identification of patients at increased risk for BOS. The association of endobronchial lymphocytic inflammation and BOS may have mechanistic implications.
肺移植为其他终末期肺部疾病带来了巨大的希望,但细支气管炎性闭塞综合征(BOS)的发展仍然限制了其生存率。尽管急性排斥反应和淋巴细胞性细支气管炎已被确定为 BOS 发展的危险因素,但尚不清楚大气道淋巴细胞炎症是否具有相同的风险。
我们评估了支气管内膜活检中的淋巴细胞性支气管炎作为 BOS 和死亡率的危险因素。
在肺移植后的监测期间收集和分级支气管内膜活检标本。我们评估了 298 例患者中在头 90 天内采集的阴性培养物的标本,并比较了通过 0-2“E 评分”评估的大气道淋巴细胞性支气管炎与急性排斥反应的标准 A 和 BR 病理学评分和小气道淋巴细胞性细支气管炎的分别。
我们发现,给定支气管镜检查中大气道和小气道淋巴细胞炎症评分之间的相关性令人惊讶地小。在活检时处于 BOS 0p 期和 BOS 1-3 期的患者中,支气管内膜淋巴细胞性支气管炎更为普遍。在移植后 90 天内,最大 E 评分的增加与 BOS 的风险增加相关(调整后的危险比,1.76;95%置信区间,1.11-2.78;P = 0.02),并且在该分析中,90 天最大 E 评分是唯一可预测 BOS 的评分类型(P < 0.01)。
这些结果支持一项多中心研究,以评估内镜活检以识别 BOS 风险增加的患者。支气管内膜淋巴细胞炎症与 BOS 的关联可能具有机制意义。